Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily

Inclusion Criteria: * Men and women at least 18 years of age who are recipients of a kidney transplant between 3 months and 5 years before the screening date * Patients taking oral Prograf® capsules twice daily, at least 2 mg total dose per day, as part of their maintenance immunosuppression therapy, with tacrolimus trough levels of 5 to 15 ng/mL * Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days before receiving study drug Exclusion Criteria: * Recipients of any transplanted organ other than kidney * Recipients of a bone marrow transplant * Patients with an eGFR (MDRD7) \< 30 mL/min at Screening * Patients with a spot protein:creatinine ratio \> 0.5 * Patients with a WBC count ≤ 2.8 ´ 109/L unless the WBC count has been stable for at least 2 weeks and the absolute neutrophil count is \> 1.0 ´ 109 /L * Patients unable to swallow study medication * Patients incapable of understanding the purposes and risks of the study, who cannot give written informed consent and who are unwilling or unable to comply with the study protocol requirements * Pregnant or nursing women * Patients with reproductive potential who are unwilling/unable to use a double barrier method of contraception * Patients who were treated with any other investigational agent within 3 months before Screening * Patients who have taken sirolimus or everolimus within 3 months before Screening * Patients on concurrent immunosuppression with MMF (CellCept) or MPS delayed-release tablets (Myfortic) who have not been on stable doses for at least 4 weeks before Screening * Patients withdrawn from corticosteroids less than 30 days before Screening * Patients with an episode of acute rejection requiring antibody therapy within 3 months before Screening * Patients treated for acute rejection within 30 days before Screening * Patients who are hepatitis C virus (HCV) negative who have received an HCV positive (HCV RNA by polymerase chain reaction or HCV antibody) donor kidney * Patients seropositive for human immunodeficiency virus * Patients with a current malignancy or a history of malignancy (within the past 5 years), except basal or nonmetastatic squamous cell carcinoma of the skin that has been treated successfully * Patients with uncontrolled concomitant infection, a systemic infection requiring treatment, or any other unstable medical condition that could interfere with the study objectives * Patients with severe diarrhea, vomiting, active peptic ulcer, or gastrointestinal disorder that may affect the absorption of tacrolimus * Patients with any form of current substance abuse, psychiatric disorder, or a condition that, in the opinion of the investigator, may invalidate communication with the investigator.